98%
921
2 minutes
20
Studies on international migrants have repeatedly found a mortality advantage of migrant over native-born populations. Data artifacts, differential prevalence of health-related behaviors, and health-related selection of immigrants and return migrants have been proposed as explanations. Neither the existence of a migrant mortality advantage for internal migrants nor the validity of existing explanations for this group have been extensively studied. Taking advantage of Finnish register data, we extend the literature on health and internal migration in four ways: 1) by using finer geographic units than previous studies, 2) by adopting models that provide more flexibility compared to alternatives based on the proportional hazard assumption, 3) by distinguishing migrants based on whether they return to their birth region (returnees) or do not (leavers), and by age at migration, and 4) by examining cause-specific mortality. We find that both leavers and returnees enjoy a mortality advantage over non-migrants. For both groups, the mortality advantage relative to non-migrants declines with age but is more pronounced for those who move above age 60 and small or negative for those who move at prime working ages. Circulatory-disease mortality accounts for more than half of the longevity advantage of both leavers and returnees. External and alcohol-related causes also contribute, particularly at younger ages. Our results challenge the idea that findings from studies of international migrants can be fully generalized to internal migrants. We demonstrate a consistent healthy migrant effect for all internal migrants, both those who leave and those who return to their region of birth.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230976 | PMC |
http://dx.doi.org/10.1016/j.socscimed.2025.118200 | DOI Listing |
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFBiotechnol J
September 2025
Joint International Research Laboratory of Agriculture and Agri-Product Safety of the Ministry of Education, Yangzhou University, Yangzhou, China.
Vaccines are pivotal in mitigating infectious diseases by reducing infection rates, severity, and mortality. Plant-derived vaccines-engineered to express antigens in plants, offer distinctive advantages, including cost-efficient production, enhanced biosafety profiles, superior thermal stability, and simplified logistics. Recent advances in plant biotechnology have enabled the large-scale production of plant-based vaccines, positioning them as a viable and transformative alternative to conventional vaccine platforms.
View Article and Find Full Text PDFNature
September 2025
Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, characterized by rapid proliferation, early metastatic spread, frequent early relapse and a high mortality rate. Recent evidence has suggested that innervation has an important role in the development and progression of several types of cancer. Cancer-to-neuron synapses have been reported in gliomas, but whether peripheral tumours can form such structures is unknown.
View Article and Find Full Text PDFMethods Cell Biol
September 2025
LR18ES03 Laboratory of Neurophysiology, Cellular Physiopathology and Valorisation of Biomolecules, Faculty of Science of Tunis, University Tunis El Manar, Tunis, Tunisia. Electronic address:
Breast cancer (BC) represents a major socio-economic challenge worldwide due to its high morbidity and mortality rates. Despite various therapeutic strategies, the heterogeneity of breast cancer and the resistance of tumour cells often lead to treatment failure. Consequently, the use of animal models of BC is crucial for understanding the cellular and molecular mechanisms involved in the different stages of carcinogenesis and for screening new drugs to assess their efficacy, potential safety and side effects.
View Article and Find Full Text PDFLangenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDF